Efficacy of Statin Therapy in Patients with Hospital Admission for COVID-19

ConclusionsStatin use in patients hospitalized with COVID-19 was associated with a reduced in-hospital mortality. The protective effect of statin was greater in those with coronary artery disease. These data support continued use of statin therapy in hospitalized patients with COVID-19. Clinical trials are needed to prospectively determine if statin use is effective in lowering the mortality in COVID-19 and other viral infections.
Source: Cardiovascular Drugs and Therapy - Category: Cardiology Source Type: research

Related Links:

MIRACLE drugs statins have emerged as the surprise weapon in the fight against COVID-19.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Experts warn findings do not prove cholesterol-lowering drugs can reduce death ratesMillions of people who take statins may be less likely to die from Covid, research suggests.The cholesterol-lowering drugs are one of the world ’s most popular medications. They can also reduce inflammation in blood vessels, which has prompted questions over whether they could help with outcomes in coronavirus patients.Continue reading...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Statins Coronavirus Medical research Science Health Source Type: news
Neth Heart J. 2021 Oct 14:1-4. doi: 10.1007/s12471-021-01637-9. Online ahead of print.ABSTRACTThe COVID-19 pandemic has spurred clinical and scientific interest in the cardiology community because of the significantly enhanced vulnerability of patients with underlying cardiac diseases. COVID-19 vaccination is therefore of vital importance to the patients we see in our clinics and hospitals every day and should be promoted by the medical community, especially cardiologists. In view of vaccine-preventable diseases, the association between influenza and cardiovascular complications has been widely investigated. Several studie...
Source: Netherlands Heart Journal - Category: Cardiology Authors: Source Type: research
ConclusionsStatin treatment had a modest negative association with COVID-19 mortality. While this finding needs confirmation from randomized clinical trials, it supports the continued use of statin treatment for medical prevention according to current recommendations also during the COVID-19 pandemic.
Source: PLoS Medicine - Category: Internal Medicine Authors: Source Type: research
AbstractStatins have been advocated as a potential treatment for coronavirus disease-2019 (COVID-19) due to its pleotropic properties. The aim of the study was to elucidate the association between antecedent statin exposure and 30-day all-cause mortality, intensive care unit (ICU) admission and hypoxic respiratory failure requiring mechanical ventilation in patients diagnosed with COVID-19. Observational cohort study derived from the VA Corporate Data Warehouse of all veterans tested positive for COVID-19 between January 1st and May 31st, 2020. Antecedent use of statins was defined as a redeemed drug prescription in the 6 ...
Source: Internal and Emergency Medicine - Category: Emergency Medicine Source Type: research
Int J Endocrinol. 2021 Sep 28;2021:9977840. doi: 10.1155/2021/9977840. eCollection 2021.ABSTRACTMETHODS: This prospective, observational study involved adult hypertensive patients with newly diagnosed type 2 diabetes mellitus at two university hospitals in Vietnam. The median time of follow-up was 4 years (August 2016-August 2020). The primary outcome was time to all-cause mortality.RESULTS: 246 patients were included with a mean age of 64.5 ± 10.4. 58.5% were females. 64.2% were categorized as high risk. At baseline, ischemic heart disease, dyslipidemia, and chronic kidney disease (CKD) were present in 54.9%, 67.1%...
Source: International Journal of Endocrinology - Category: Endocrinology Authors: Source Type: research
This study aimed to investigate the protective effects of lovastatin in intensive care unit (ICU) patients with COVID-19. The case-control study consists of 284 ICU patients, which classified into three groups as follows: 1) the patients who no received lovastatin as a control (92 patients), 2) patients received 20 mg per day lovastatin (99 patients), and 3) patients received 40 mg per day lovastatin (93 patients). Each group's demographic and clinical parameters, along with CRP, interleukin (IL)-6, IL-8 levels, and mortality rate, were studied in three-time points. The results showed that there was no statistically signif...
Source: International Immunopharmacology - Category: Allergy & Immunology Authors: Source Type: research
Biomed Res Int. 2021 Sep 23;2021:1901772. doi: 10.1155/2021/1901772. eCollection 2021.ABSTRACTBACKGROUND: Although vaccine rollout for COVID-19 has been effective in some countries, there is still an urgent need to reduce disease transmission and severity. We recently carried out a meta-analysis and found that pre- and in-hospital use of statins may improve COVID-19 mortality outcomes. Here, we provide an updated meta-analysis in an attempt to validate these results and increase the statistical power of these potentially important findings.METHODS: The meta-analysis investigated the effect of observational and randomized c...
Source: Biomed Res - Category: Research Authors: Source Type: research
Atherosclerosis progresses undetected and is known as the silent killer. Bu...Read more on AuntMinnie.comRelated Reading: How has the COVID-19 pandemic affected CT CAC testing? CT shines when it comes to COVID-19 risk stratification CT CAC helps determine which patients benefit from statin therapy JAMA Internal Medicine stirs debate on coronary CT AI predicts cardiovascular risk on LDCT lung cancer screening
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
Acute respiratory distress syndrome is a heterogenous syndrome with many etiologies for which there are no definitive pharmacologic treatments, despite decades of research. We explore some adjunctive pharmacologic therapies, including neuromuscular blockade, corticosteroids, and inhaled pulmonary vasodilators. Additionally, we explore some investigative therapies, including Vitamin C, beta-agonists, statins, mesenchymal stromal cells, and granulocyte –macrophage colony stimulating factor. We do discuss the potential role of steroids in acute respiratory distress syndrome with severe acute respiratory syndrome coronav...
Source: Critical Care Clinics - Category: Intensive Care Authors: Source Type: research
More News: Cardiology | Cardiovascular | Cholesterol | Clinical Trials | COVID-19 | Heart | Statin Therapy